Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- ICPT -4.1%, CYOU -1.6%, VDTH -1.4%
Other news:
- TENX -36.2% (provides regulatory update following discussions regarding path forward for levosimendan; is continuing its review of strategic alternatives)
- DRYS -6.7% (provides another Kalani Investments update)
- CLVS -5.4% ( to collaborate with Bristol-Myers (BMY) to evaluate the combination of Opdivo and Rubraca in pivotal phase 3 clinical trials in Advanced ovarian cancer and Advanced triple-negative breast cancers)
- REGN -3.1% (maybe be related to item in SNY earnings which reported partnered drug dupixent revs of ~$30 mln)
- SNAP -2.8% (lockup expiration, accd to CNBC)
- FEYE -2.5% (report of a possible data breach)
- IBKR -1.7% (files for Class A Common Stock common stock shelf offering)
- RYAAY -1.5% (Barron's profiles cautious view on Ryanair)
Analyst comments:
- HTZ -5.4% (downgraded to Underweight from Equal Weight at Barclays)
- EGO -3.5% (downgraded to Underperform from Neutral at Credit Suisse)
- CFR -1.5% (downgraded to Underweight from Neutral at JP Morgan)
- ULTA -0.7% (downgraded to Perform from Outperform at Oppenheimer)